NCT07640685 UCLA Magnesium Formulation Athlete Study
| NCT ID | NCT07640685 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Los Angeles |
| Condition | Athletic Performance |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-10-05 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2026-10-05 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind, placebo-controlled trial will compare magnesium glycinate, magnesium L-threonate, and placebo in UCLA varsity athletes. Participants will complete a baseline monitoring period followed by 4 weeks of blinded nightly supplementation. WHOOP 4.0 data will be used to evaluate sleep efficiency, total sleep time, sleep consistency, heart rate variability, resting heart rate, and recovery metrics. Baseline and final testing will assess selected reaction and physical performance outcomes. The primary outcome is change in WHOOP-derived sleep efficiency from baseline week to final treatment week.
Eligibility Criteria
Inclusion Criteria: * Age 18-35 years. * Current NCAA Division I athlete at UCLA. * Actively participating in team training and/or competition. * Willing to wear a WHOOP 4.0 device continuously during the baseline and treatment periods of the study block. * Able to swallow oral capsules and follow supplement instructions. * Able and willing to complete daily REDCap surveys and weekly check-ins during the study block. * Fluent in English. * Able to provide informed consent. Exclusion Criteria: * Known kidney disease or impaired renal function, assessed by participant-completed screening questions and review by the PI or designated study clinician. Screening asks about known kidney disease, reduced kidney function, dialysis, a history of abnormally high magnesium, and prior medical advice to avoid magnesium supplementation. A positive or uncertain response requires clinician review. If safety cannot be established from the questionnaire and participant interview alone, the athlete will not be enrolled. The study will not access medical records or perform research laboratory testing for this screening. * Current use of non-study magnesium supplements within the past 30 days or unwillingness to avoid non-study magnesium supplements during the study unless approved by the study clinician. * Diagnosed or treated sleep disorder likely to confound sleep outcomes, such as untreated or unstable insomnia, sleep apnea, or regular use of sleep medication expected to affect study outcomes. * Known difficulty swallowing capsules or history of choking. * Known allergy or sensitivity to magnesium or inactive capsule ingredients. * Known current pregnancy or breastfeeding, determined by participant self-report; no pregnancy testing is planned for this minimal-risk study. A participant who becomes pregnant or begins breastfeeding during the study will stop study product and notify the study team. Additional exclusionary circumstances include use of magnesium-containing laxatives or antacids during the study unless approved by the study clinician, or significant recent or planned changes in training load, diet, sleep medication, or recovery supplements that the investigator believes would confound interpretation.
Contact & Investigator
Jeremy Swisher, MD
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT07640685 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Athletic Performance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07640685 currently recruiting?
Yes, NCT07640685 is actively recruiting participants. Contact the research team at jswisher@mednet.ucla.edu for enrollment information.
Where is the NCT07640685 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07640685 clinical trial?
NCT07640685 is sponsored by University of California, Los Angeles. The principal investigator is Jeremy Swisher, MD at University of California, Los Angeles. The trial plans to enroll 150 participants.